Although the prognosis of papillary thyroid cancer (PTC) is extremely good, locoregional recurrences after initial treatment occur. Thyroglobulin (Tg) is a reliable tumor marker to detect recurrence or persistence of PTC. However, occasionally serum Tg may miss the detection of a recurrence. We report a 54-year-old female presented with hoarseness due to cervical recurrence without concomitant elevation of serum Tg and anti-Tg antibody, in contrast to extremely increased needle-washout Tg, who had undergone a total thyroidectomy and radioiodine ablation as initial therapies for PTC. Several factors causing such discrepancy between needlewashout Tg and serum Tg can be suggested including site of recurrence, volume of tumor, interference by some kind of plasma antibodies other than anti-Tg antibody, and any conformational defect of Tg protein. Among them, the most convincing explanation is that any conformational defect of Tg may lead to impaired secretion of Tg to blood. We suggest that more studies are needed to find the cause for potential mechanisms involved in PTC recurrences without increased serum Tg.
INTRODUCTION
Although the vast majority of patients with papillary thyroid cancer (PTC) have an excellent prognosis, disease recurrences do occur. During follow-up after initial surgery and/or radioiodine therapy, serum thyroglobulin (Tg) measurement, neck ultrasound, and/or diagnostic whole-body radioiodine scan are recommended depending on the risk for recurrence in a patient with PTC [1, 2] .
Particularly, serum Tg is the most sensitive biomarker of recurrence for well-differentiated thyroid cancer. Since Tg is synthesized only by thyroid follicular cells, measurements of serum Tg provide important information about the presence of residual, recurrent, or metastatic disease in patients with differentiated thyroid cancer [3] .
However, occasionally serum Tg may miss the detection of a recurrence. Here, we report a case of cervical recurrence without a concomitant increase in serum Tg and anti-Tg antibody in a patient with PTC who had undergone a total thyroidectomy and radioiodine ablation as initial therapies.
CASE REPORT
A 54-year-old female with suspicious malignant nodule in thy- (Fig. 2) . Stimulated serum Tg level obtained after thyroxine withdrawal was 9.56 μg/L and serum TSH level was 64.81 mU/L.
She was followed by clinical examination, assessment of serum Tg levels and anti-Tg antibody, and ultrasound of the neck every 6 to 12 months without evidence of disease. TSH suppression therapy by levothyroxine was maintained to achieve a serum TSH less than 0.10 mU/L (Table 1) .
At 3 years after surgery, she complained of hoarseness for the past 
DISCUSSION
According to recent Korean [1] and American [2] management guideline for patients with thyroid cancer, measurements of serum Tg, anti-Tg antibody and TSH at 6-to 12-month intervals and neck ultrasound 6 to 12 months postoperatively and then periodically depending on the patient's risk for recurrent disease are recommended. Tg is a highly sensitive and specific marker for detection of recurrent or residual disease after initial therapy [3] . After total thyroidectomy and radioiodine ablation, serum Tg levels would be expected to be very low (<1 to 2 μg/L), either on TSH suppression therapy or after thyroid hormone withdrawal, if the patient is cured [4] . As a single investigation, serum Tg measurement is more sensitive than radioiodine uptake scanning [5] [6] [7] [8] [9] . Previous studies suggested that patients with low levels of serum Tg during suppression therapy may have a high probability of being free of disease [10, 11] . Further pathologic examination by electron microscope may be needed. Second, the site of recurrence may influence serum Tg level. Patients with distant metastases to lung or bone have higher Tg levels than those with lymph node metastases [11] . Our patient had metastases only to cervical lymph nodes and no distant metastases.
However, this fact may explain the result of negative serum Tg, but not that of high needle-washout Tg level. Third, the volume of metastatic tumor may be too small to increase serum Tg level enough [17, 18] . Bachelot et al. [17] [20] . However, we could not identify HAB interference in patient's serum.
The present case has some limitations. Most of all, serum Tg level after thyroid hormone withdrawal were not measured. However, it is usually adopted measuring of serum Tg on thyroxine because of its high sensitivity and the inconvenience of withdrawal of thyroid hormone. Furthermore, patients with a TSH-suppressed serum Tg concentration < 0.1 μg/L were unlikely to have an stimulated Tg above 2.0 μg/L [21] .
In summary, we report an unusual case of PTC recurrence without a concomitant increase in serum Tg and anti-Tg antibody, in contrast to extremely increased needle-washout Tg, in a patient who had undergone a total thyroidectomy and radioiodine ablation as initial therapies. It is important that PTC patients need to be followed by clinical examination and ultrasound of the neck as well as assessment of serum Tg levels and anti-Tg antibodies. We suggest that more studies are needed to find the cause for potential mechanisms involved in PTC recurrences without concomitant elevation of serum Tg levels in the absence anti-Tg antibody.
